Global Hematocrit Testing Market Revenue Grows at a CAGR of 6.12%.

Introduction

Straits Research released its highly anticipated report, “Global Hematocrit Testing Market Size & Outlook, 2026-2034”. According to the study, the market size is valued at USD 2.05 billion in 2025 and is projected to expand to USD 3.48 billion by 2034, registering a compound annual growth rate (CAGR) of 6.12%.

Market Dynamics

The global hematocrit testing market is experiencing steady expansion, driven primarily by the increasing global incidence of anemia and other blood-related disorders among aging populations. As chronic diseases such as kidney disorders, cardiovascular conditions, and nutritional deficiencies become more prevalent, the demand for routine hematocrit measurement continues to surge in both clinical and point-of-care settings. This rise in diagnostic need is further supported by improvements in healthcare accessibility and growing emphasis on early detection, positioning hematocrit assessment as a critical component of comprehensive patient evaluation.

Despite this strong momentum, the market faces a notable restraint in the form of high equipment and maintenance costs associated with advanced hematology analyzers. Many small clinics, rural healthcare centers, and resource-limited regions struggle to afford modern automated systems and the recurring expenses of specialized reagents and calibration materials. Additionally, disparities in laboratory infrastructure and trained personnel further limit widespread adoption in low-income markets where basic diagnostic capabilities remain underdeveloped.

Nevertheless, a significant opportunity lies in the rapid technological evolution of portable hematocrit testing devices. Innovations such as handheld analyzers, microfluidic platforms, and low-volume sampling technologies are enabling faster, cost-effective, and more accessible diagnostic solutions. These advancements are particularly valuable for emergency care, home-based monitoring, and decentralized healthcare models. As manufacturers focus on affordable device development and expand distribution in high-growth regions, the adoption of portable hematocrit testing solutions is expected to accelerate, creating strong future growth potential for the global market.

Key Highlights

• Product: The consumables & reagents segment dominated the market in 2025, accounting for 39.67% revenue share.
• Application: The leukemia segment is estimated to grow at the fastest pace with a CAGR of 7.88% in 2026-2034.
• End Use: The hospitals segment dominated the market, accounting for 49.71% revenue share in 2025.
• Regional Insights: North America dominated the global market, accounting for 39.05% share in 2025, owing to the strong adoption of automated hematology analyzers.

Competitive Players

1. Abbott
2. Agappe Diagnostics
3. BD
4. bioMérieux SA
5. Bio‑Rad Laboratories, Inc.
6. Danaher
7. EKF Diagnostics Holdings plc
8. Hoffmann-La Roche Ltd.
9. Grifols S.A.
10. HemoCue AB
11. Heska Corporation
12. Hilab
13. HORIBA, Ltd.
14. Mindray Medical International Limited
15. Nihon Kohden Corporation
16. Nova Biomedical
17. Sensa Core
18. Siemens Healthineers
19. Sysmex Corporation
20. Thermo Fisher Scientific, Inc.
21. Others

Recent Developments

February 2025: CytoChip received the FDA’s 510(K) clearance for its automated hematology analyzer Cito CBC System. 

Segmentation

1. By Product (2026-2034)
   1. Hematocrit Test Meters
      1. Hand-held POC Meters
      2. Benchtop Meters
   2. Analyzers & Centrifuge
   3. Consumables & Reagents
2. By Application (2026-2034)
   1. Anemia
   2. Leukemia
   3. Polycythemia Vera
   4. Congenital Heart Diseases
   5. Kidney Disease
   6. Others
3. By End Use (2026-2034)
   1. Hospitals
   2. Diagnostic Labs
   3. Others